About ZEPATIER

About ZEPATIER® (elbasvir and grazoprevir)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg1

Please consult the ZEPATIER SmPC before prescribing.

12 weeks ZEPATIER achieved an overall cure rate (SVR) of 95% (291/306) for treatment-naive patients (ref 4)

The C-EDGE Treatment Naïve study was an international, randomised, blinded, placebo-controlled, parallel-group trial of a fixed-dose combination of grazoprevir 100 mg/elbasvir 50 mg for treatment-naïve cirrhotic and non-cirrhotic patients with chronic HCV GT1, GT4, or GT6 infections. A historical SVR12 rate was used as the comparator for efficacy.

Drug-drug interactions and dosing of ZEPATIER

Find out more >

ZEPATIER has demonstrated efficacy in People who inject drugs2

ZEPATIER for all stages of chronic kidney disease (CKD)3

References

  1. ZEPATIER Summary of Product Characteristics.
  2. Dore GL et al, Ann Int Med. 2016;doi:10.7326/M16-0816 [Epub ahead of print].
  3. Roth D et al. Lancet. 2015:386:1537-1545.
  4. Zeuzem S et al. Ann Intern Med. 2015; 163:1-13.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-ZEP-00165 | Date of Preparation: June 2024